Active Biotech Past Earnings Performance
Past criteria checks 0/6
Active Biotech has been growing earnings at an average annual rate of 12.7%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 54.1% per year.
Key information
12.7%
Earnings growth rate
34.1%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -54.1% |
| Return on equity | -169.3% |
| Net Margin | n/a |
| Next Earnings Update | 04 May 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Active Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -58 | 15 | 43 |
| 30 Sep 22 | 0 | -60 | 15 | 44 |
| 30 Jun 22 | 0 | -57 | 15 | 41 |
| 31 Mar 22 | 0 | -54 | 14 | 40 |
| 31 Dec 21 | 0 | -50 | 15 | 35 |
| 30 Sep 21 | 6 | -38 | 14 | 30 |
| 30 Jun 21 | 6 | -35 | 13 | 28 |
| 31 Mar 21 | 6 | -32 | 13 | 25 |
| 31 Dec 20 | 7 | -32 | 13 | 26 |
| 30 Sep 20 | 1 | -39 | 13 | 27 |
| 30 Jun 20 | 2 | -40 | 13 | 27 |
| 31 Mar 20 | 3 | -36 | 13 | 26 |
| 31 Dec 19 | 8 | -34 | 12 | 28 |
| 30 Sep 19 | 12 | -32 | 11 | 29 |
| 30 Jun 19 | 16 | -31 | 11 | 33 |
| 31 Mar 19 | 21 | -35 | 10 | 38 |
| 31 Dec 18 | 20 | -37 | 11 | 39 |
| 30 Sep 18 | 21 | -88 | 11 | 40 |
| 30 Jun 18 | 21 | -88 | 11 | 40 |
| 31 Mar 18 | 20 | -103 | 19 | 45 |
| 31 Dec 17 | 20 | -109 | 20 | 49 |
| 30 Sep 17 | 22 | -63 | 21 | 56 |
| 30 Jun 17 | 21 | -67 | 22 | 58 |
| 31 Mar 17 | 20 | -59 | 16 | 58 |
| 31 Dec 16 | 19 | -60 | 16 | 58 |
| 30 Sep 16 | 17 | -86 | 16 | 71 |
| 30 Jun 16 | 18 | -97 | 17 | 82 |
| 31 Mar 16 | 17 | -152 | 17 | 128 |
Quality Earnings: 0GQU is currently unprofitable.
Growing Profit Margin: 0GQU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0GQU is unprofitable, but has reduced losses over the past 5 years at a rate of 12.7% per year.
Accelerating Growth: Unable to compare 0GQU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0GQU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 0GQU has a negative Return on Equity (-169.28%), as it is currently unprofitable.